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OBJECTIVES The aim of the study was to test the value of low dose aspirin associated with standard oral
anticoagulants (OAC) after mechanical mitral valve replacement (MMRV) to reduce strands,
thrombi and thromboembolic events.
BACKGROUND Strands and thrombi are thought to increase the risk of embolic events after MMVR,
particularly in the immediate postoperative period.
METHODS Two hundred twenty-nine patients were prospectively recruited: 109 patients (group A1)
were randomly assigned to aspirin (200 mg per day) with OAC and 120 patients (group A2)
to OAC alone (international normalized ratio 2.5 to 3.5). All patients were subjected to
multiplane transesophageal echocardiography at nine days and five months and were followed
up for one year.
RESULTS At nine days and five months, there was a high and comparable incidence of strands in the
two groups (group A1: 44%, 58%; group A2: 49%, 63%). However, the incidence of
nonobstructive periprosthetic valve thrombi was significantly lower in group A1 at 9 days: 5%
versus 13%, p 5 0.03.
Total thromboembolic events were reduced in group A1 (9% vs. 25%, p 5 0.004) although
there was an increased incidence of gastrointestinal hemorrhage (7% vs. 0%). Overall
mortality was 9% in group A1 and 4% in group A2. Valve-related events were similar in
both groups. Early thrombi, but not strands, were associated with higher morbidity, especially
thromboembolic events (30% vs. 13%, p 5 0.003).
CONCLUSIONS One year after MMVR, the association of aspirin with OAC reduced thrombi and
thromboembolic events, but not morbidity, due to an increase in hemorrhagic complications.
(J Am Coll Cardiol 2000;35:739–46) © 2000 by the American College of Cardiology
Despite progress in valve design with new generation
prostheses such as the St. Jude medical valve, patients with
prosthetic mechanical mitral prostheses have an increased
incidence of cardiac embolic events (1–3), particularly in the
immediate postoperative period (4–8).
Transesophageal echocardiographic examinations (TEE)
early in the postoperative period have shown a high inci-
dence of strands or thrombi (9–12) attached to mechanical
mitral prostheses. These accretions are now thought to
influence morbidity (9,11,13,14) after mechanical valve
replacement.
The benefit of early therapy with a combination of aspirin
and an oral anticoagulant (OAC) after mechanical mitral
valve replacement (MMVR) has yet to be established. In a
prospective study (15), Turpie et al. demonstrated that
adding aspirin decreased thromboembolic events and mor-
tality although the meta-analyses are not in total agreement
(4,16). The association of 160 mg/day aspirin was regarded
as optional (17,18).
In order to determine the value of the association of low
dose aspirin after MMVR, we undertook a prospective
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randomized comparison of OAC alone with OAC plus
aspirin in patients receiving a St. Jude medical prosthesis at
the mitral position.
METHODS
Patients. The inclusion criterion for the study was the
implantation of a St. Jude medical mechanical mitral valve.
Patients were not included if they were unwilling to give
informed consent or if they had contraindications to aspirin,
anticoagulant therapy or transesophageal examination.
Study design and treatment protocol. In a randomized,
controlled design, patients were allocated to one of two
groups at random: the reference group was treated with
OACs alone to maintain the international normalized ratio
(INR) between 2.5 to 3.5, while the test group received a
supplement of 200 mg aspirin from the first postoperative
day along with the same anticoagulant treatment. The INR
was 2.5–3.5 as recommended for the new generation of
mechanical mitral prostheses (17,18).
Patients received antiulcer treatment systematically. The
follow-up was essentially clinical, but all patients benefited
from transthoracic and transesophageal multiplane echocar-
diographic examinations. All patients were subjected to a
preoperative coronary angiographic evaluation. Coronary
artery disease (CAD) was defined as more than 50%
narrowing of the lumen in at least one coronary artery.
Mitral valve replacements (MVR) were all performed by
the same surgical unit and postoperative anticoagulation was
standardized: intravenous infusion of heparin was started
from the sixth postoperative hour (19); the dose was
adjusted based on a tabular normogram and supplemented
with three subcutaneous calcium heparin injections per day
during the 24 postoperative hours to maintain an aPPT of
twice the control valve. Oral anticoagulation was instituted
48 h after operation and subcutaneous injection of calcium
heparin was continued until the INR had returned to 2.
INR was then monitored to keep it in the target range 2.5
to 3.5. The patient’s cardiologist was allowed to adjust the
target range in the presence of embolic risk factors (20).
Echocardiographic study. The echocardiographic study
was standardized and the operators were unaware of the
treatment received by the patients. Transthoracic echocar-
diography (TTE) and TEE examinations were carried out
in all patients eight days and five months after MVR using
a Hewlett Packard Sonos 2500 (Imaging System, Andover)
and a multiplane probe. The examinations were performed
by five experienced operators and were recorded on video-
tapes. The technique was standardized and focused on the
prosthesis with transgastric views for the ventricular side of
the prosthesis and transesophageal views for each portion of
the valves using the multiplane probe. Particular attention
was focused on leaflet mobility, strands and thrombi (inci-
dence, size and localization). Strands were defined as mobile
linear echodense structures attached to the prostheses. They
were generally less than 1 mm in width and several mm in
length (Fig. 1). Thrombi were defined as well defined and
circumscribed echodense masses attached to the prostheses
and clearly seen throughout the cardiac cycle (Fig. 2). They
were usually situated at the level of the atrial side of the
sewing ring and were localized or ring-shaped. We also
searched for the presence of thrombi in the left atrium or
left appendage. Spontaneous echo contrast was considered
grade 1 for low intensity echoes and grade 2 in the event of
well defined spirals. The transesophageal echocardiograms
were all reviewed independently by two experienced echo-
cardiographers. In cases of discordance, a consensus was
reached with the opinion of a third experienced echocardi-
ographer.
Surgical technique. Prosthetic leaflets were implanted in
the antianatomic orientation, and the prostheses were an-
chored to the valve annulus by a continuous suture.
Follow-up procedure. All the patients were subjected to
clinical, laboratory and echocardiographic examinations at
different times during the first operative year. All data were
collected prospectively with the first day in-hospital as day
1. Patients were monitored prospectively by regular exami-
Abbreviations and Acronyms
CAD 5 coronary artery disease
GIB 5 gastrointestinal bleeding
INR 5 international normalized ratio
MMVR 5 mechanical mitral valve replacement
MVR 5 mitral valve replacement
OAC 5 oral anticoagulant
RR 5 relative risk
TEE 5 transesophageal echocardiography
TTE 5 transthoracic echocardiography
Figure 1. TEE view of a St. Jude medical mitral valve showing a
strand on the atrial side of the prosthesis. TEE 5 transesophageal
echocardiography.
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nations during the first postoperative year using a case
report form filled out by the cardiologist and patients’
general physicians. Data were collected and verified (includ-
ing hospital visits for each patient) at one month, six months
and one year.
End points and definitions. The primary outcome of the
study was the composite triple end point of death, major
thromboembolic events or major hemorrhage at one-year of
follow-up. Death was defined as any death, regardless of
cause. Thromboembolic events were classified as major or
minor: major thromboembolic events were based on clinical
criteria and included: stroke defined as a focal neurologic
deficit of sudden onset that persisted for more than 24 h if
a computerized tomographic scan of the brain excluded
bleeding as a possible cause; coronary artery embolism,
which was defined as the occurrence of acute ischemia in
patients with previously normal coronary arteries; peripheral
embolism was defined as the occurrence of acute ischemia
caused by an embolism documented by angiography or
surgery; valve thrombosis, which was defined as the depo-
sition on the valve of a large obstructive thrombus necessi-
tating surgery or fibrinolysis. Minor thromboembolic events
included: nonobstructive prosthetic thrombi detected by
systematic TEE and transient ischemic attacks defined as a
focal neurologic deficit of sudden onset that persisted for
less than 24 h.
Bleeding events were also classified as major or minor:
major hemorrhage was defined as that associated with a
sudden fall of 20 g per liter or more in hemoglobin level and
necessitating a transfusion of at least two units of blood or
any hemorrhage necessitating surgery and any intracranial
bleeding. Other hemorrhages were considered to be minor
but were all recorded. Hospital and late deaths as well as
valve-related events were strictly defined according to the
guidelines of the American Association for Thoracic Sur-
gery (21).
Statistical analysis. The primary analysis included all ran-
domized patients (intention to treat). The Fisher exact test
was used to compare the two treatment groups with respect
to the primary end point. A logistic regression model was
used to study predictive factors of events at 1 year. The p
value indicating statistical significance was set at 0.05.
RESULTS
Patients. From July 1994 to July 1996, 263 consecutive
patients underwent an MVR with a St. Jude medical
prosthesis in our department. Thirty-four patients were
excluded on the grounds described in the Methods section,
and 109 patients were assigned at random to receive OACs
with 200 mg of aspirin per day and 120 to receive OACs
alone.
Both groups were similar with respect to the important
baseline characteristics that may influence outcome (Table
1). Patients were relatively old (mean age 63 years); frac-
tional shortening was 31% in both groups; concomitant
procedures were 48% similar in both groups (coronary artery
bypass grafting was performed in 13% of patients and aortic
replacement in 40% of patients). The patients were all
followed up during the first postoperative year and none
were lost to follow-up.
Anticoagulation in the two groups. During the first post-
operative year, the mean international normalized ratio was
3.04 6 0.25: 3.04 in the aspirin group and 3.03 in the
reference group. The mean INR was in the target range in
79% of patients, below it in 7% and above it in 13% of
patients without any significant difference between the two
groups. aPPT and INR were also similar in the two groups
during the early postoperative period.
Echocardiographic results. Early postoperative echocardi-
ography (day 9). Transesophageal echocardiography was
performed in 218 patients on day 9 (three patients died
before TEE, three refused it and in five the examination
could not be performed due to tamponade or hemodynamic
instability). There was no difference in incidence of strands
between the two groups although there was a reduced
incidence of thrombi in the aspirin group (13.1% to 4.8%,
p 5 0.03). In both groups thrombi were generally small,
localized on the atrial side of the sewing ring (mean width
4.2 mm) and nonobstructive and none required reoperation
(Table 2).
Fifth month echocardiographic results. A second TEE
was performed on 186 patients (12 patients died before the
echocardiography study; 21 refused it; 2 patients lived too
far away and in 8 patients the TEE was not carried out for
medical reasons). There was a comparably high incidence of
strands (61%) in the two groups at five months. Thrombi
were less frequent than in the early postoperative period (6%
vs. 9%), and in the aspirin group there was a lower incidence
of thrombi (4% vs. 8%) with a smaller size (6 vs. 4 mm), but
the difference was not statistically significant (Table 3).
Figure 2. TEE view of a St. Jude medical mitral valve showing
nonobstructive thrombus on the atrial side of the prosthesis.
TEE 5 transesophageal echocardiography.
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RESULTS
Principal outcome events (Table 4). Mortality at one year
was higher, but not significantly so, in the aspirin group (9%
vs. 4%). Total thromboembolic events were observed in 9%
of group A1 versus 25% of group A2 (p 5 0.004).
However, in the group with aspirin, there was a higher
incidence of gastrointestinal bleeding (GIB) (7% vs. 0%).
The incidence of the primary outcome of the study (mor-
tality, major thromboembolic events and major hemor-
rhage) did not differ significantly (29% group A1 vs. 16%
group A2). Valve-related events were 36% in both groups.
Mortality. The early mortality (30 days—including hospi-
tal mortality) was 3.5%; six patients in the aspirin group
(three myocardial failure, two septic shock, one GIB) and
two patients (myocardial failure) in the group without
aspirin.
The late mortality was 4%: four patients (two sudden
death, one cardiac failure, one malignancy) in the aspirin
group and three patients (one sudden death, one malig-
nancy, one traumatic) in the group without aspirin. The
total valve-related mortality was 4.8%: 7.3% in the aspirin
group and 2.5% in the group without aspirin (not signifi-
cant).
Thromboembolic events. Major embolic events occurred
in five (4.1%) of the 120 patients in the group without
aspirin (one prosthetic thrombosis necessitating surgery and
four stroke) and in one (0.9%) of the 109 patients in the
aspirin group (one peripheral embolism).
Minor embolic events occurred in 25 (20.8%) patients in
the group without aspirin (18 prosthetic nonobstructive
thrombi and seven transient ischemic attacks) and in nine
(7.5%) patients in the group with aspirin (five prosthetic
Table 1. Baseline Characteristics
Total
Group
A1*
Group
A2†
Number of patients 229 109 120
Age (yrs) 63 63 63
Male gender 115 61 54
P diameter‡ (mm) 29 29.5 29.2
Valve pathology
Regurgitation 149 (65.0%) 70 (64.2%) 79 (65.8%)
Stenosis 25 (10.9%) 12 (10.9%) 13 (10.8%)
Combined 35 (15.2%) 16 (14.6%) 19 (15.8%)
Endocarditis 18 (7.8%) 10 (9.1%) 8 (6.6%)
Pannus 2 (0.8%) 1 (0.8%) 1 (0.8%)
Rhythm nonsinus 112 (48.9%) 54 (49.5%) 58 (48.3%)
Shortening fraction 31% 31% 32%
LAD§ (mm) 48 49 47
Thromboembolic history 34 (14.8%) 19 (17.4%) 15 (12.5%)
CAD 35 (15.2%) 21 (19.2%) 14 (11.6%)
Concomitant procedures (% of patients) 112 (48.4%) 54 (49.5%) 58 (48.3%)
CABG 31 (31.5%) 19 (16.4%) 12 (10%)
Aortic (SJM) replacement 92 (40.1%) 42 (38.5%) 50 (41.6%)
Tricuspid valve repair 8 (3.4%) 4 (3.6%) 4 (3.3%)
*Group with aspirin; †group without aspirin; ‡prosthetic diameter; §left atrial diameter.
CABG 5 coronary artery bypass grafting; CAD 5 coronary artery disease; LAD 5 left atrial diameter; SJM 5 St. Jude
medical valve.
Table 2. Incidence of Strands and Thrombi at Nine Days
Number (%) of Patients
Total A1 A2
p
Value
Number of patients 218 104 114
TEE (postoperative days) 9.1 9.2 9.1
Strands 102 (46.7%) 46 (44.2%) 56 (49.1%) ns
Thrombi 20 (9.1%) 5 (4.8%) 15 (13.1%) 0.03
Thrombi width (mm) 4.2 4.6 4.1 ns
Strands length (mm) 7.1 7.1 7.1 ns
TEE 5 transesophageal echocardiography
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nonobstructive thrombi and four transient ischemic at-
tacks).
Total thromboembolic events (also including 23 nonob-
structive thrombi) occurred in 10 (9.1%) of the aspirin-
treated patients and in 30 (25%) of the group without
aspirin (p 5 0.004). The incidence of thromboembolic
events (excluding prosthetic nonobstructive thrombi, which
depended on the day the TEE was performed) fell over time
(Fig. 3). Five (29.4%) occurred during the first postoperative
month and none occurred after the eighth month.
Hemorrhagic complications. Major hemorrhage occurred
in 31 patients (13.5%). This was significantly more frequent
in the aspirin group (21 patients, 19.2%) than in the group
without aspirin (10 patients, 8.3%, p 5 0.02). These major
hemorrhages were often tamponade (15 patients, 6.5%), but
eight patients (3.4%), all in the aspirin group, developed
gastrointestinal bleeding. Other forms of hemorrhage in-
cluded hematoma (three patients), hemothorax (two pa-
tients) and genitourinary bleeding (three patients).
The difference between the two groups was due solely to
the increase in gastrointestinal bleedings (eight vs. 0, p 5
0.003). Major hemorrhage decreased markedly with time
(Fig. 3); 16 (51.6%) occurred in the first postoperative
month and only two (6.4%) in the last six months. Minor
hemorrhage (essentially epistaxis, hematoma and genitouri-
nary) occurred in 45 patients (19.6%): 25 (22.9%) in the
group with aspirin and 20 (16.6%) in the group without
aspirin.
Reoperations. Reoperations were comparable in both
groups: five (one endocarditis, three perivalvular leaks and
one hemolysis) in the aspirin group and four (three perival-
vular leaks and one hemolysis) in the control group.
Quality of anticoagulation and late morbidity. Seventy-
two percent of patients with late thromboembolic events
had INR ,2.5 and, for the late major hemorrhages, 76%
occurred in patients with an INR .3.5.
Early thrombi and morbidity. It can be seen from the
results in Table 5 that the early incidence of thrombi was
associated with more valve-related events (50% vs. 27%) due
primarily to a higher incidence of thromboembolism (30%
vs. 13%, p 5 0.0003, relative risk ([RR]) 5 6.3).
Risk factors of morbidity. After multivariate analysis (Ta-
ble 6), only thromboembolic history emerged as an inde-
pendent risk factor of morbidity (p 5 0.04).
DISCUSSION
This study represents the largest randomized trial compar-
ing OAC to OAC plus aspirin after MMVR with the same
bileaflet valves. It is the first study comparing OAC and the
association of an antiaggregant with an OAC using the
lower INR range of 2.5–3.5 currently recommended for the
new generation prostheses. The patients were evaluated
both clinically and by TEE examinations over a one year
period after operation.
Table 3. Incidence of Strands and Thrombi at Five Months
Total A1 A2
p
Value
Number of patients 186 87 99
Strands 114 (61.2%) 51 (58.6%) 63 (63.6%) ns
Thrombus 12 (6.4%) 4 (4.5%) 8 (8%) ns
Thrombi width (mm) 5.7 4 6.6 ns
Table 4. Principal Outcome Events at One Year
Number (%) of Patients
Total A1 A2
p
Value
Number of patients 229 109 120
Mortality 15 (6.5%) 10 (9.1%) 5 (4.1%) ns
Major hemorrhages 31 (13.5%) 21 (19.2%) 10 (8.3%) 0.02
Major thromboembolic events 6 (2.6%) 1 (0.9%) 5 (4.1%) ns
End point events 52 (22.7%) 32 (29.3%) 20 (16.6%) ns
Minor thromboembolic events 34 (14.8%) 9 (8.2%) 25 (20.8%) 0.007
Reoperation 9 (3.9%) 5 (4.5%) 4 (3.3%) ns
Total thromboembolic events 40 (17.4%) 10 (9.1%) 30 (25%) 0.001
Number of patients with events 88 (38.4%) 42 (38.5%) 46 (38.3%) ns
Number of patients with valve related events 84 (36.6%) 40 (36.6%) 44 (36.6%) ns
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Study limitations. We did not administer placebo in the
test group with OAC alone, but it was a randomized
prospective design and blind concerning the echocardio-
graphic study. The aspirin dosage, 200 mg, is debatable and
a lower dosage (80 mg) could be as efficient and less
gastrotoxic, but we did not wish to depart from the doses
recommended in vascular pathology. It was close to the
160 mg dose of the American College of Chest Physicians’
recommendations and the guidelines of the European So-
ciety of Cardiology.
Morbidity. The early mortality of 3.4% and late mortality
of 3% at one year were comparable with the data in the
literature. Similar results have been reported by Baudet
(3.8% and 2.4% patient year) (5) and Jegaden (3.5% and
2.6% patient year) (22) on late survival after MVR with the
St. Jude medical prosthesis.
Our morbidity data were also comparable with those of
other authors. Total thromboembolic events (17.4%) seem
high, especially in the group without aspirin (25%) because
nonobstructive prosthetic thrombi discovered by early TEE
were included. After excluding these thrombi, our total
thromboembolic events of: 7.4% at one year (10% in the
group without aspirin) were comparable with literature data.
Butchard (7) demonstrated that linearized rates of throm-
boembolic events were 21% patient year in the first month
after MVR (21% also in our study) and 9% each month
from the first to the fifth month (6% in our study) and 2.5%
during the last month of the first postoperative year (1.8% in
this study).
With respect to major bleeding, in the patients treated
with anticoagulant alone, our rates were consistent with
those reported in the review from Petitti (23) of anticoag-
ulant therapy. As in other studies, the incidence of hemor-
rhage decreased during the first postoperative year; for
Landefeld (8) it decreased from 3% per month during the
first month to 0.8% per month during the first year and
0.3% thereafter.
In the patients treated with aspirin, our gastrointestinal
bleeding rate of 7% was similar to the 6% patient-year of
Chesebro (24) but higher than the 3% patient year reported
by Turpie (15). This may be accounted for, in part, by the
lower dose of enteric-delayed aspirin used and by the higher
rates of hemorrhagic complications after the first postoper-
ative months. In our study, there was no evidence of
gastrointestinal bleeding after the fourth month.
OAC associated with antiaggregant after MVR. Studies
differ in terms of type and localization of valve prosthesis
used, but also in INR range and in aspirin doses. The
studies of Altman (25) and Dale (26) were carried out on
ball prostheses, while that of Chesebro (24) had a high INR
range and that of Turpie (15) was carried out on various
types of prosthesis including bioprostheses and different
localizations. We focused here on the St. Jude medical
mitral prosthesis.
Altman (25) found a benefit for the combined treatment,
but Dale did not. In the study of Chesebro (24) the increase
in major hemorrhage overrode the benefit of the decrease in
incidence of thromboembolic complications, and the trial
was stopped. In the Canadian study, the decrease in
thromboembolic events and deaths offset the increase in
major hemorrhage, and the combined treatment was
thought beneficial. We noted in our study a decrease in
Figure 3. Cumulative risk of thromboembolic events (excluding
nonobstructive thrombi) and of major hemorrhages.
Table 5. Early Thrombi and Morbidity
Number (%) of Patients
TH1 TH2 p Value
Number of patients 20 198
Mortality 3 (15%) 9 (4.5%) ns
Major hemorrhages 1 (5%) 27 (13.6%) ns
Thromboembolism events* 6 (30%) 9 (13.6%) p 5 0.0003
RR 5 6.3
Reoperation 0 9 (4.5%)
Total events 10 (50%) 54 (27.2%) p 5 0.01
RR 5 1.9
Valve related events 10 (50%) 51 (25.7%) p 5 0.008
RR 5 2
*Thromboembolism events excluding prosthetic nonobstructive thrombi.
RR 5 relative risk; TH1 5 patients with thrombus; TH2 5 patients without thrombus.
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thromboembolic events but with a corresponding increase in
major hemorrhage and a corresponding increase, albeit
slight, in mortality in the aspirin group. We could not,
therefore, conclude that aspirin offered any overall benefit.
In the two published meta-analyses comparing both treat-
ments, Cappelleri (16) concluded in favor, while Cannegi-
eter (4) advised against the combined treatment. We feel
that the combination is only likely to benefit a subgroup of
patients with high thromboembolic risk.
In the study of Turpie (15), 30% of patients had CAD,
and the benefit in the group with aspirin was largely due to
the reduction in sudden death, deaths due to acute myocar-
dial infarction and to acute heart failure (1 vs. 12). More-
over, in the group without aspirin, 21% of patients with
CAD died or had thromboembolic events against only 2%
of the patients with CAD in the aspirin group. The
association of aspirin may, thus, be of more benefit in
patients with CAD. Thromboembolic events, but also
major hemorrhages, are more frequent in the early postop-
erative period, so it does not seem advisable to restrict
aspirin just to the early postoperative period.
The association of aspirin is probably of value in patients
with echographically demonstrated thrombi in view of their
high risk of thromboembolic complications. We showed
here that this association reduced both the size and number
of these thrombi. A thromboembolic history also emerged
as a risk factor of morbidity. Nevertheless, we did not
identify any particular subgroup that significantly benefited
from the aspirin/anticoagulant combination.
Anticoagulation and morbidity. Our results are in agree-
ment with previously reported studies (27,28), with most of
the major hemorrhages being observed in patients receiving
too intense anticoagulation and most of the thromboem-
bolic events occurring in patients with inadequate antico-
agulation. Anticoagulant therapy, thus, needs to be titrated
accurately after MVR in order to minimize complications.
So the AREVA (29) study (aortic prosthesis) recommends
a less intense anticoagulation to reduce the risk of hemor-
rhagic events. Nevertheless, in a Canadian study (30),
patients treated with aspirin plus warfarin at a lower target
INR of 2.0 to 2.5 had equivalent antithrombotic efficacy but
without reduction of bleeding compared with patients with
aspirin plus warfarin at an INR of 3.0 to 3.5. However,
adjustment of target INR may be required in the presence of
patient-related embolic risk factors (19), and, in our sub-
group of patients with related embolic risk factors, the target
INR could have been higher. In fact, these patients were
often more intensely anticoagulated by their cardiologists.
So, in our subgroup of patients with thromboembolic
history, which we found had a higher risk of thromboem-
bolic events, the INR (3.2) was higher.
Conclusion. After MVR, there is a high incidence of fibrin
strands, which was not reduced by administration of aspirin.
On the other hand, the presence of early thrombi after
MVR leads to increased morbidity and risk of thromboem-
bolic events, which are reduced by aspirin. Systematic early
postoperative TEE, thus, would seem to be of value to
detect these often asymptomatic thrombi with a potentially
high thromboembolic risk.
The early association of aspirin with OAC after MVR
reduced thromboembolic events but also increased gastro-
intestinal bleeding and did not reduce overall morbidity 1
year after MVR by the St. Jude medical prosthesis.
In summary, we do not recommend the systematic
association of aspirin with OAC after MVR, but the
intensity of OAC should be adapted according to the
patient related risk factors. This association may prove more
beneficial in the subgroups of patients with high thrombo-
embolic risk such as those with a thromboembolic history,
Table 6. Risk Factors of Morbidity
Morbidity* p Value
Number of patients† 88/229
Thromboembolic history yes 20/34 (58.8%) 0.01
Thromboembolic history no 68/195 (34.8%) RR 5 1.6 (1.2–2.3)
Cardiomegaly yes 18/49 (36.7%) 0.006
Cardiomegaly no 31/180 (17.2%) RR 5 2.1 (1.3–3.4)
Fractional shortening ,25% 9/34 (26.4%) ns
Fractional shortening .25% 79/195 (40.5%)
Nonsinus rhythm yes 42/112 (37.5%) ns
Nonsinus rhythm no 46/117 (39.3%)
Thrombi (i.e) yes 10/20 (50%) 0.01
Thrombi (i.e) no 54/198 (27.2%) RR 5 1.9 (1.2–3)
Strands (i.e) yes 42/102 (41.1%)
Strands (i.e) no 37/116 (31.8%) ns
Spontaneous echo contrast (i.e) yes 30/98 (30.6%) ns
Spontaneous echo contrast (i.e) no 49/120 (40.8%)
*Patients with end points events; †number of patients with events.
Multivariate analysis: thromboembolic history: p 5 0.04.
(i.e) 5 initial examination; RR 5 relative risk.
745JACC Vol. 35, No. 3, 2000 Laffort et al.
March 1, 2000:739–46 Aspirin and OAC Does Not Reduce Morbidity After MMRV
those where thrombi were detected by TEE soon after
operation and probably those with associated CAD.
Acknowledgments
We thank Chene G, MD from the Service d’Information
Me´dicale, Department of Medical Information (Pr R.
Salamon) of the University Hospital of Bordeaux for her
valuable assistance with the statistical analysis.
Reprint requests and correspondence: Dr. Patrick Laffort,
Service de Cardiologie Pr Roudaut, Hoˆpital Haut-Leveque, Ave-
nue de Magellan, 33604 Pessac, France. E-mail: lfr.Cardio@
bordeaux.inserm.fr.
REFERENCES
1. Michel PL, Acar J. Prothe`ses valvulaires me´caniques et biologiques et
traitements antithrombotiques. In: Samama MM, Acar J, editors.
Traitement Antithrombotique, Masson Edit. 3rd edition. Paris, 1998:
143–75.
2. Acar J, Michel PL, Iung B. Les accidents thromboemboliques des
prothe`ses valvulaires: incidence, pre´vention et traitement en 1997.
Sang Thrombose Vaisseaux 1997;9:172–8.
3. Aupart M, Diemont F, Babuty S, et al. Re´sultats interme´diaires avec
la prothe`se valvulaire a` ailettes CarboMedics. Arch Mal Coeur
1997;90:457–62.
4. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and
bleeding complications in patients with mechanical heart valve pros-
theses. Circulation 1994;89:635–41.
5. Baudet EM, Puel V, McBride JT, et al. Long-term results of valve
replacement with the St. Jude medical prosthesis. J Thorac Cardiovasc
Surg 1995;109:858–70.
6. Butchard EG, Lewis PA, Grunkemeier GL, et al. Low risk of
thrombosis and serious embolic events despite low intensity anticoag-
ulation. Circulation 1988;78 Suppl I:166–77.
7. Butchard EG, Lewis PA, Bethel JA, et al. Adjusting anticoagulation
to prosthesis thrombogenecity and patient risk factors: recommenda-
tions for the Medtronic Hall valve. Circulation 1991;84 Suppl III:
61–9.
8. Landefeld CS, Goldman L. Major bleeding in outpatients treated with
warfarin: incidence and prediction by factors known at the start of
outpatient therapy. Am J Med 1989;87:144–52.
9. Iung B, Cormier B, Dadez E, et al. Small abnormal echos after mitral
valve replacement with bileaflet mechanical prostheses: predisposing
factors and effect on thromboembolism. J Heart Valve Dis 1993;2:
259–66.
10. Bonnefoy E, Perinetti M, Girard C, et al. Echocardiographie transoe-
sophagienne syste´matique dans les 24 premie`res heures postope´ratoires
apre`s remplacement valvulaire mitral. Arch Mal Coeur 1995;88:315–9.
11. Malergue MC, Temkine J, Slama M, et al. Inte´reˆts de l’e´chocardio-
graphie transoesophagienne syste´matique postope´ratoire pre´coce des
remplacements valvulaires mitraux. Une e´tude prospective sur 50
patients. Arch Mal Coeur 1992;85:1299–304.
12. Gue´ret P, Vignon P, Fournier P, et al. Transesophageal echocardiog-
raphy for the diagnosis and management of nonobstructive thrombosis
of mechanical mitral valve prosthesis. Circulation 1995;91:103–10.
13. Orsinelli DA, Pearson AC. Detection of prosthetic valve strands by
transesophageal echocardiography: clinical significance in patients with
suspected cardiac source of embolism. J Am Coll Cardiol 1995;26:
1713–8.
14. Freedberg RS, Goodkin GM, Perez JL, et al. Valve strands are
strongly associated with systemic embolization: a transesophageal
echocardiographic study. J Am Coll Cardiol 1995;26:1709–12.
15. Turpie AGG, Gent M, Laupacis A, et al. A comparison of aspirin
with placebo in patients treated with warfarin after heart-valve replace-
ment. N Engl J Med 1993;329:524–9.
16. Cappelleri JC, Fiore LD, Brophy MT, et al. Efficacy and safety of
combined anticoagulant and antiplatelet therapy versus anticoagulant
monotherapy after mechanical heart-valve replacement: a meta-
analysis. Am Heart J 1995;130:547–52.
17. Stein PD, Alpert JS, Dalen JE, et al. Antithrombotic therapy in
patients with mechanical and biological prosthetic heart valves. Chest
1998;114:602s–10s.
18. Chesebro TH, Fuster RV. Optimal antithrombotic therapy for me-
chanical prosthetic heart valves. Circulation 1996;94:2055–6.
19. Baudet E. Anticoagulation chez les porteurs de prothe`ses valvulaires
cardiaques. Mouv Card Vasc 1995;1:229–32.
20. Gohlke-Barwolf C, Acar J, Oakley C, et al. Guidelines for prevention
of thromboembolic events in valvular heart disease. Eur Heart J
1995;16:1320–30.
21. Edmunds LH, Clark RE, Cohn LH, et al. Guidelines for reporting
morbidity and mortality after cardiac valvular operations. J Thorac
Cardiovasc Surg 1988;96:351–3.
22. Jegaden O, Eker A, Delahaye F. Thromboembolic risk and late
survival after mitral valve replacement with the St. Jude medical valve.
Ann Thorac Surg 1994;58:172–8.
23. Petitti DB, Strom BL, Melmon KL. Duration of warfarin anticoag-
ulant therapy and the probabilities of recurrent thromboembolism and
hemorrhage. Am J Med 1986;81:255–9.
24. Chesebro JH, Adams PC, Fuster V, et al. Antithrombotic therapy in
patients with valvular heart disease and prosthetic heart valves. J Am
Coll Cardiol 1986;8:41B–56B.
25. Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of
thromboembolic complications in patients with substitute heart valves.
J Thor Cardiovasc Surg 1976;72:127–9.
26. Dale JD, Myhre E, Storstein O, et al. Prevention of arterial throm-
boembolism with acetylsalicylic acid. Am Hear J 1977;94:101–11.
27. Farah E, Enriquez-Sarano M, Vahanian JP, et al. Thromboembolic
and hemorrhagic risk in mechanical and biological aortic prostheses.
Eur Heart J 1984;5 Suppl D:43–7.
28. Fuster V, Pumphrey CW, Mc Goon MD, et al. Systemic thrombo-
embolism in mitral and aortic Starr-Edwards prostheses: a 10–19 year
follow-up. Circulation 1982;66 Suppl I:I157–61.
29. Acar J, Iung B, Boissel JP, et al. AREVA: multicenter randomized
comparison of low doses versus standard dose anticoagulation in
patients with mechanical prosthetic heart valves. Circulation 1996;94:
2107–12.
30. Turpie AGG, Gent M, Cruickshank MK, et al. Randomized com-
parison of moderate (INR 3.0–3.5) with low intensity (INR 2.0–3.5)
anticoagulant therapy in patients with prosthetic heart valves treated by
aspirin (100 mg/day). Circulation 1998;98 Suppl 1:768.
746 Laffort et al. JACC Vol. 35, No. 3, 2000
Aspirin and OAC Does Not Reduce Morbidity After MMRV March 1, 2000:739–46
